drugset / Trial / NCT00241488

DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia

NCT00241488

Phase 3 Completed 1362 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.

Timeline

Start
2003-06
Primary completion
2005-12
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg

Indications

No indication recorded.